Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

Pancreatic Cancer Clinical Trial

Official title:

Real World Status of Palliative Care for Pancreatic Cancer Patients in China-a National Multi-center Cross-sectional Survey

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06090825
• Other study ID #: K4602
• Status: Recruiting
• Start date: September 1, 2023
• Est. completion date: September 1, 2025

Study information

• Verified date: October 2023
• Source: Peking Union Medical College Hospital
• Contact: Qiaofei Liu
• Phone: 8615201693370
• Email: qfliu[@]aliyun.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Description:

Pancreatic cancer is a highly malignant gastrointestinal tumor with only a 10% overall 5-year survival rate. More than 80% of patients are already in the advanced stage when diagnosed, losing the chance of surgery. Advanced pancreatic cancer progresses rapidly and chemoradiotherapy has limited efficacy, so palliative care is thought to play an important role in the treatment process. However, due to the late development of palliative care, there is a lack of data on real-world clinical palliative care for pancreatic cancer patients in China.

This study investigates the real-world current status of palliative care for pancreatic cancer patients by sending a web questionnaire to the doctors from the Department of General Surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland. The survey aims to obtain the real status of palliative care and achieve a comprehensive understanding of how to develop palliative care in hospitals.

The questionnaire includes both subjective standards like the surgeons' opinion on the development of palliative therapy and objective standards such as dedicated beds and teams for palliative care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: September 1, 2025
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Doctors from the General Surgery Department in Chinese public tertiary teaching hospitals and public primary care units

• Approval to participate

• Participants with a valid and complete questionnaire evaluated by 2 experienced surgeons

Exclusion Criteria:

• Refusal to participate

• Participants with an invalid or incomplete questionnaire

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Other:
• Observational study
Observational study

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Descriptions and scores of real status of hospice care in different hospitals	The primary outcome is objective standards and subjective scores of current status of palliative care to qutify the development of palliative care of different hospitals. The score is evaluated by a follow-up questionnaire. The maximum and minimum score is 10 and 0, respectively.	1 month